Advance your antibody therapeutics pipeline with Revvity's comprehensive preclinical services. Our preclinical CRO services support monoclonal antibodies (mAbs), bispecific antibodies, antibody drug conjugates (ADCs), antibody fragments, biosimilars, and engineered formats, helping you accelerate discovery, optimize candidates, and de‑risk development with decision‑ready data.
Why choose Revvity's services for antibody therapeutics?
- Expertise: Our team have solid experience across modalities to support your antibody drug discovery, screening, biosimilar characterization, and mechanism-of-action studies.
- Decision-ready data: Get reliable data to help you make informed decisions and progress toward IND-enabling studies.
- Flexible engagement: Benefit from our standardized assays or bespoke programs tailored to your therapeutic strategy.
- Advanced technologies: We have access to a range of technologies, including CRISPR screening, Pin-point™ base editing, and high-content imaging to deeply understand your biologic by dissecting mechanism of action.
- Translatable models: 2D/3D cell systems and immune-relevant assays for oncology, immunology, and infectious disease.
Our antibody therapeutics services
Candidate screening and profiling
Evaluate binding, specificity, and efficacy across diverse cell panels. Identify optimal candidates with high-throughput assays, phenotypic screening, monoclonal antibody preclinical testing, and biosimilar comparability studies.
Evaluate binding, specificity, and efficacy across diverse cell panels. Identify optimal candidates with high-throughput assays, phenotypic screening, monoclonal antibody preclinical testing, and biosimilar comparability studies.
Mechanism-of-action and resistance mapping
Use CRISPR pooled and arrayed screens to uncover genes that modulate antibody efficacy, sensitivity, and resistance. Support rational optimization, bispecific antibody development strategies, biosimilar functional equivalence testing, patient stratification, and combination therapies.
Use CRISPR pooled and arrayed screens to uncover genes that modulate antibody efficacy, sensitivity, and resistance. Support rational optimization, bispecific antibody development strategies, biosimilar functional equivalence testing, patient stratification, and combination therapies.
Immune involvement and immunogenicity
Assess immune recruitment, effector function, and cytokine responses with ImmuSignature™ assays. Optimize structure for safety and selectivity with our preclinical immune cell screening services, including biosimilar immunogenicity profiling.
Assess immune recruitment, effector function, and cytokine responses with ImmuSignature™ assays. Optimize structure for safety and selectivity with our preclinical immune cell screening services, including biosimilar immunogenicity profiling.
Cell model engineering
Develop fit‑for‑purpose models with knock‑in/knockout variants and multiplex base editing to support novel antibody therapeutics and biosimilar development. Validate targets, assess comparability, assess mechanism of action including ADC bystander effects, and enhance translational relevance across antibody discovery and preclinical programs.
Develop fit‑for‑purpose models with knock‑in/knockout variants and multiplex base editing to support novel antibody therapeutics and biosimilar development. Validate targets, assess comparability, assess mechanism of action including ADC bystander effects, and enhance translational relevance across antibody discovery and preclinical programs.
ADC-specific services
For programs involving antibody‑drug conjugates, we provide specialized services support including:
For programs involving antibody‑drug conjugates, we provide specialized services support including:
- Linker stability testing to ensure controlled payload release.
- Payload cytotoxicity profiling across OncoSignature™ tumor panels.
- Comparative mechanism studies to differentiate ADC activity from unconjugated antibodies or payloads.
- Combination strategy development to maximize ADC efficacy in oncology.
Explore our dedicated Antibody‑Drug Conjugate services for more details.
Platforms and technologies
- OncoSignature screening platform: Diverse tumor panels in 2D/3D for potency and selectivity.
- HTRF™, Alpha technology, and high-content imaging: Multiparametric readouts for mechanism, efficacy and pathway engagement.
- CRISPR libraries: Genome-wide and targeted discovery of resistance and sensitizer genes.
- ImmuSignature assays: Immune cell-based evaluation across multiple donors.
- Pin-point™ base editing platform: Precision engineering of target genes, including cell surface targets.
- Cell line engineering: Knock-in/knock-out model and reporter cell line generation.
Partner with Revvity
Our preclinical services for antibody therapeutics provide the insight and flexibility you need to move confidently from discovery to candidate selection. Whether you require rapid screening or bespoke mechanistic studies, our preclinical services team can help deliver the clarity to accelerate your drug development pipeline.
Get in touch today to discuss your antibody therapeutics program.
Featured resources
You may also be interested in:
